Brit J Cancer:性别在转移性结直肠癌先天性和适应性免疫微环境中的作用

2020-05-26 MedSci原创 MedSci原创

这些数据证明了雄鼠和雌鼠对转移性CRC的免疫反应中存在生存相关的差异。雌鼠表现出细胞因子产生的变化,伴随着免疫细胞数量的增加,偏向Th2表型。在此模型中,CRC免疫反应的关键差异与生存率相关。

结直肠癌(CRC)女性患者比男性患者具有明显的生存优势。尽管对CRC的免疫反应很重要,但性别对肿瘤微环境(TME)的影响尚不十分清楚。近日,肿瘤领域权威杂志British Journal of Cancer上发表了一篇研究文章,研究人员假设性别所致的免疫反应不同可能有助于生存。

研究人员使用转移性CRC的小鼠模型,评估了局部和全身T细胞、巨噬细胞和细胞因子情况,并通过基于多重磁珠的阵列测量TME和血清细胞因子,同时使用FCA鉴定细胞和表型。IHC提供了T细胞浸润的形态学证据。

雌鼠具有存活率和T细胞浸润率提高。CD8、CD4和Th2种群与小鼠更长的生存期相关。雄鼠血清趋化因子和炎症相关细胞因子水平升高。在TME中,雄鼠细胞因子水平低于雌鼠,并且外周的细胞因子梯度较小。雌鼠肿瘤中IL-10+巨噬细胞数量增加,且与生存期有关。

这些数据证明了雄鼠和雌鼠对转移性CRC的免疫反应中存在生存相关的差异。雌鼠表现出细胞因子产生的变化,伴随着免疫细胞数量的增加,偏向Th2表型。在此模型中,CRC免疫反应的关键差异与生存率相关。这些差异支持跨TME的多方面转变。

原始出处:

Anita L. Ray.et al.The role of sex in the innate and adaptive immune environment of metastatic colorectal cancer.British Journal of Cancer.2020.https://www.nature.com/articles/s41416-020-0913-8

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1814227, encodeId=9b28181422efb, content=<a href='/topic/show?id=0c4094e0431' target=_blank style='color:#2F92EE;'>#适应性免疫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94704, encryptionId=0c4094e0431, topicName=适应性免疫)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Fri Nov 13 11:38:24 CST 2020, time=2020-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1369505, encodeId=34b01369505c1, content=<a href='/topic/show?id=bc9f28589d0' target=_blank style='color:#2F92EE;'>#先天性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28589, encryptionId=bc9f28589d0, topicName=先天性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Thu May 28 10:38:24 CST 2020, time=2020-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386628, encodeId=500d1386628ee, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu May 28 10:38:24 CST 2020, time=2020-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453386, encodeId=9fe5145338664, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Thu May 28 10:38:24 CST 2020, time=2020-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621035, encodeId=7d981621035d2, content=<a href='/topic/show?id=dccc94e01c9' target=_blank style='color:#2F92EE;'>#适应性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94701, encryptionId=dccc94e01c9, topicName=适应性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b13a20191510, createdName=huhuaidong394, createdTime=Thu May 28 10:38:24 CST 2020, time=2020-05-28, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1814227, encodeId=9b28181422efb, content=<a href='/topic/show?id=0c4094e0431' target=_blank style='color:#2F92EE;'>#适应性免疫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94704, encryptionId=0c4094e0431, topicName=适应性免疫)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Fri Nov 13 11:38:24 CST 2020, time=2020-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1369505, encodeId=34b01369505c1, content=<a href='/topic/show?id=bc9f28589d0' target=_blank style='color:#2F92EE;'>#先天性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28589, encryptionId=bc9f28589d0, topicName=先天性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Thu May 28 10:38:24 CST 2020, time=2020-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386628, encodeId=500d1386628ee, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu May 28 10:38:24 CST 2020, time=2020-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453386, encodeId=9fe5145338664, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Thu May 28 10:38:24 CST 2020, time=2020-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621035, encodeId=7d981621035d2, content=<a href='/topic/show?id=dccc94e01c9' target=_blank style='color:#2F92EE;'>#适应性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94701, encryptionId=dccc94e01c9, topicName=适应性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b13a20191510, createdName=huhuaidong394, createdTime=Thu May 28 10:38:24 CST 2020, time=2020-05-28, status=1, ipAttribution=)]
    2020-05-28 huirong
  3. [GetPortalCommentsPageByObjectIdResponse(id=1814227, encodeId=9b28181422efb, content=<a href='/topic/show?id=0c4094e0431' target=_blank style='color:#2F92EE;'>#适应性免疫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94704, encryptionId=0c4094e0431, topicName=适应性免疫)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Fri Nov 13 11:38:24 CST 2020, time=2020-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1369505, encodeId=34b01369505c1, content=<a href='/topic/show?id=bc9f28589d0' target=_blank style='color:#2F92EE;'>#先天性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28589, encryptionId=bc9f28589d0, topicName=先天性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Thu May 28 10:38:24 CST 2020, time=2020-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386628, encodeId=500d1386628ee, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu May 28 10:38:24 CST 2020, time=2020-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453386, encodeId=9fe5145338664, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Thu May 28 10:38:24 CST 2020, time=2020-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621035, encodeId=7d981621035d2, content=<a href='/topic/show?id=dccc94e01c9' target=_blank style='color:#2F92EE;'>#适应性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94701, encryptionId=dccc94e01c9, topicName=适应性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b13a20191510, createdName=huhuaidong394, createdTime=Thu May 28 10:38:24 CST 2020, time=2020-05-28, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1814227, encodeId=9b28181422efb, content=<a href='/topic/show?id=0c4094e0431' target=_blank style='color:#2F92EE;'>#适应性免疫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94704, encryptionId=0c4094e0431, topicName=适应性免疫)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Fri Nov 13 11:38:24 CST 2020, time=2020-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1369505, encodeId=34b01369505c1, content=<a href='/topic/show?id=bc9f28589d0' target=_blank style='color:#2F92EE;'>#先天性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28589, encryptionId=bc9f28589d0, topicName=先天性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Thu May 28 10:38:24 CST 2020, time=2020-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386628, encodeId=500d1386628ee, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu May 28 10:38:24 CST 2020, time=2020-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453386, encodeId=9fe5145338664, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Thu May 28 10:38:24 CST 2020, time=2020-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621035, encodeId=7d981621035d2, content=<a href='/topic/show?id=dccc94e01c9' target=_blank style='color:#2F92EE;'>#适应性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94701, encryptionId=dccc94e01c9, topicName=适应性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b13a20191510, createdName=huhuaidong394, createdTime=Thu May 28 10:38:24 CST 2020, time=2020-05-28, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1814227, encodeId=9b28181422efb, content=<a href='/topic/show?id=0c4094e0431' target=_blank style='color:#2F92EE;'>#适应性免疫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94704, encryptionId=0c4094e0431, topicName=适应性免疫)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Fri Nov 13 11:38:24 CST 2020, time=2020-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1369505, encodeId=34b01369505c1, content=<a href='/topic/show?id=bc9f28589d0' target=_blank style='color:#2F92EE;'>#先天性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28589, encryptionId=bc9f28589d0, topicName=先天性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Thu May 28 10:38:24 CST 2020, time=2020-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386628, encodeId=500d1386628ee, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu May 28 10:38:24 CST 2020, time=2020-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453386, encodeId=9fe5145338664, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Thu May 28 10:38:24 CST 2020, time=2020-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621035, encodeId=7d981621035d2, content=<a href='/topic/show?id=dccc94e01c9' target=_blank style='color:#2F92EE;'>#适应性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94701, encryptionId=dccc94e01c9, topicName=适应性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b13a20191510, createdName=huhuaidong394, createdTime=Thu May 28 10:38:24 CST 2020, time=2020-05-28, status=1, ipAttribution=)]

相关资讯

Circulation:2000年-2014年,急性心肌梗死发病率变化趋势的性别差异

近几十年来,美国急性心肌梗死(AMI)的发病率有所下降,但性别差异依然存在。在一个综合医疗服务系统中,Mefford等人研究了AMI事件在女性和男性中的时间趋势。研究人员在加利福尼亚州南部凯萨医疗机构中35岁及以上住院患者中筛选AMI患者。根据第九版临床修订的《国际疾病分类》鉴别2000年-2014年期间首次住院治疗的急性心肌梗死、ST段抬高型心肌梗死和非ST段抬高型心肌梗死患者。计算平均年变化百

JACC:外周动脉疾病患者预后的存在性别差异

外周动脉疾病(PAD)会增加主要不良心血管事件(MACE)的风险。本研究的目的旨在评估PAD患者的MACE风险的性别差异。本EUCLID临床研究纳入分析了13885名PAD患者(女性占28%),不同性别患者之间的PAD严重程度和药物治疗无明显差异。女性患者的年龄更大(p < 0.001),且糖尿病、高血压高脂血症和慢性肾脏疾病的概率更大。经过平均30个月时间的随访,女性患者的MACE风险更低

NEURON:研究人员绘制AD风险网络图谱

有证据表明,阿尔茨海默病(AD)的三大风险因素之间存在相互作用:年龄、APOE基因型和性别。

为何新冠肺炎男性病亡率高于女性

根据美国约翰斯·霍普金斯大学最新数据,截至美国东部时间25日19时,新冠肺炎全球确诊病例已超过46.6万例,死亡病例超过2.1万例。

JACC:PCI术后5年女性的主要不良心血管事件发生风险更高

对经皮冠状动脉介入治疗(PCI)后与性别相关的预后研究报道存在相互矛盾的结果。本研究旨在探讨PCI术后5年心血管结局的性别相关风险。

JACC:国内学者揭示年龄-性别在血管硬化中的交互作用

动脉硬化是血管老化过程的中心环节。传统上,血管研究主要集中在动脉粥样硬化性血管疾病上,而动脉僵硬并没有引起太多的关注。本研究的目的是评估面临心血管疾病高负担的中国人群动脉硬化的终生轨迹,尤其是年龄-性别的相互作用和潜在的决定因素。本研究纳入分析了80415名检测过肱踝脉搏波速度(baPWV)的正常人群,结果表明年龄相关的动脉硬化程度存在性别差异,从青春期到58岁的男性血管硬化程度更高,而此后的女性